The UK life science company COMPASS Pathways receives FDA approval for a clinical trial using psilocybin to treat treatment-resistant depression.
Researchers find that psilocybin changes blood flow, communication pathways, and activity in the brain, enabling "a state of unconstrained cognition."
Researchers find the psychosis produced from psilocybin in humans is due to activation of serotonin 2A receptors.
Alexander and Ann Shulgin publish "TiHKAL: The Continuation."
Alexander and Ann Shulgin publish "PiHKAL: A Chemical Love Story."